5,253 trials (keyword fallback)
Acute Biphenotypic Leukemia · Acute Lymphoblastic Leukemia in Remission · Acute Myeloid Leukemia in Remission
Primary: Time to Neutrophil Engraftment — 20.0; 22.0 days
Hematologic Neoplasms
Primary: Number of Recipients Who Developed Grades I-IV Acute Graft Versus Host Disease (GVHD) Following a Combination of Cyclosporine and a Mini-dose Methotrexate Regimen for…
Leukemia · Lymphoma
Primary: Complete Remission (CR) — 50; 50; 14; 11 participants
Accelerated Phase Chronic Myelogenous Leukemia · Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative · Blastic Phase Chronic Myelogenous Leukemia
Primary: Response Rate Including Complete Response, Partial Response, and Hematological Improvement Assessed by Blood Cell Counts, Number of Blasts in Bone Marrow, and Clinical…
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Acute Myeloid Leukemia With Gene Mutations
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Adult Acute Lymphoblastic Leukemia in Remission · Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 · Blastic Phase
Primary: Relapse Free Survival — 3 Participants
Leukemia
Primary: Number of Participants Who Died and Had Serious Adverse Events (SAEs), Related SAEs, Adverse Events (AEs) Leading to Discontinuation, Related AEs Leading to…
Myeloid Leukemia, Chronic, Accelerated Phase · Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Primary: Percent of Participants With Major Hematologic Response (MaHR) With 6 Months of Follow-up From Date of Last Enrollment - Randomized Population — 48.0; 47.9 percentage of…
Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Time to Failure — 16; 13 Days
Myelogenous Leukemia, Chronic
Primary: Major Molecular Response Rate (MMR) at 12 Months Between All 3 Arms - With Imputation — 22.3; 44.3; 42.7 Percentage of participants — p=<0.0001
Leukemia, Acute Myelogenous (AML) · Leukemia, Acute Lymphocytic (ALL) · Leukemia, Chronic Myelogenous (CML)
Primary: Toxicity — 5 participants
Leukemia · AML · MDS
Primary: Participants With a Complete Response — 34 Participants
Philadelphia Chromosome Positive · Chronic Myelogenous Leukemia in Chronic Phase
Primary: MMR Rate at 12 Mos. of Nilotinib Treatment on Study in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Who…
Myeloid Leukemia, Chronic, Chronic-Phase
Primary: Percent of Participants With Major Cytogenetic Response (MCyR) at 6 Months Follow-Up — 51.8; 49.0 percentage of Participants
Acute Myelogenous Leukemia · Acute Myeloid Leukemia
Primary: Percentage of Participants Achieving Overall Remission (OR) After No More Than Two Cycles (Approximately Month 2) — 45.5; 37.5; 8.0; 3.6 percentage of participants